Health

In a recent study presented at the annual meeting of the International Gynecologic Cancer Society, the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) has shown promising response rates in heavily pretreated patients with HER2-expressing gynecologic cancers. Dr. Ritu Salani from the University of California Los Angeles highlights the significance of trastuzumab deruxtecan in the field of
0 Comments
Serial infusions have emerged as a potential solution in restoring amniotic fluid lost due to the lack of fetal renal development before 26 weeks’ gestation. This groundbreaking approach has significantly improved the rate of live births among cases of fetal bilateral renal agenesis, a condition that is otherwise uniformly lethal. The RAFT trial, which investigated
0 Comments
Myelodysplastic syndromes (MDS) pose a significant challenge in clinical management, particularly for patients with lower-risk disease who relapse or have refractory disease. The IMerge trial investigated the efficacy of imetelstat, a first-in-class telomerase inhibitor, in achieving red blood cell (RBC) transfusion independence in this patient population. The IMerge trial, led by Dr. Uwe Platzbecker and
0 Comments
The so-called “Take Care of Maya” trial recently culminated in a shocking $261 million verdict, implicating Johns Hopkins All Children’s Hospital of Florida for a multitude of claims. Among them were charges of wrongful death, emotional distress, and false imprisonment. The Kowalski family asserted that the hospital inaccurately labeled Beata Kowalski as the perpetrator of
0 Comments
Medical professionals have long awaited breakthroughs in the treatment options for atopic dermatitis. As advancements in psoriasis treatments became increasingly promising, those focused on atopic dermatitis found themselves eagerly waiting for their turn. However, with the introduction of biologics in 2017, there was finally a glimmer of hope. While having one treatment option was a
0 Comments
In a recent presentation at the International Gynecologic Cancer Society annual meeting, Dr. Roisin O’Cearbhaill discussed the safety and efficacy of ubamatamab (REGN4018), an investigational bispecific antibody, in patients with recurrent ovarian cancer. The results of the phase I study showed that ubamatamab, either alone or in combination with the PD-1 inhibitor cemiplimab (Libtayo), demonstrated
0 Comments
A recent extension of a randomized trial has shown that total thyroidectomy significantly improves patient-reported general health in euthyroid Hashimoto’s thyroiditis for up to 5 years. The study, conducted by Dr. Geir Hoff and colleagues at the University of Oslo in Norway, measured the quality of life using the Short Form-36 Health Survey. The initial
0 Comments